Splicing Interruption by Intron Variants in CSNK2B Causes Poirier–Bienvenu Neurodevelopmental Syndrome: A Focus on Genotype–Phenotype Correlations

Wen Zhang1,2,3, Fanghua Ye1, Shimeng Chen1,2,3, Jing Peng1,2,3, Nan Pang1,2,3* and Fei Yin1,2,3*

1 Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China, 2 Hunan Intellectual and Developmental Disabilities Research Center, Changsha, China, 3 Clinical Research Center for Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University, Changsha, China

CSNK2B has recently been identified as the causative gene for Poirier–Bienvenu neurodevelopmental syndrome (POBINDS). POBINDS is a rare neurodevelopmental disorder characterized by early-onset epilepsy, developmental delay, hypotonia, and dysmorphism. Limited by the scarcity of patients, the genotype–phenotype correlations in POBINDS are still unclear. In the present study, we describe the clinical and genetic characteristics of eight individuals with POBINDS, most of whom suffered developmental delay, generalized epilepsy, and hypotonia. Minigene experiments confirmed that two intron variants (c.367+5G>A and c.367+6T>C) resulted in the skipping of exon 5, leading to a premature termination of mRNA transcription. Combining our data with the available literature, the types of POBINDS-causing variants included missense, nonsense, frameshift, and splicing, but the variant types do not reflect the clinical severity. Reduced casein kinase 2 holoenzyme activity may represent a unifying pathogenesis. We also found that individuals with missense variants in the zinc finger domain had manageable seizures (p = 0.009) and milder intellectual disability (p = 0.003) than those with missense variants in other domains of CSNK2B. This is the first study of genotype–phenotype correlations in POBINDS, drawing attention to the pathogenicity of intron variants and expanding the understanding of neurodevelopmental disorders.

Keywords: CSNK2B, Poirier–Bienvenu neurodevelopmental syndrome, genotype, phenotype, intron variants

INTRODUCTION

Poirier–Bienvenu neurodevelopmental syndrome [Online Mendelian Inheritance in Man (OMIM) #618732, POBINDS] is a recently described rare autosomal dominant neurodevelopmental disorder characterized by early-onset seizures, developmental delay, hypotonia, and dysmorphism (Ernst et al., 2021). POBINDS is caused by a de novo variant in the CSNK2B gene
(located at 6p21.33), which encodes the casein kinase 2 enzyme β subunit (CK2β). CK2 is a ubiquitous protein serine/threonine kinase, a heterotetrameric enzyme consisting of two catalytic CK2α or CK2α' subunits and two regulatory β subunits (Niefind et al., 2001). CK2β is a highly conserved regulatory subunit, and excessive synthesis of CK2β will form dimers that disrupt the complete structure and function of CK2 (Graham and Litchfield, 2000; Niefind et al., 2001). In previous studies, CK2 was found to be widespread in the brain (Guerra et al., 1999), and conditional knockout of CSNK2B mice induced age-dependent reduction of grip strength and impaired neuromuscular transmission and synaptic gene expression (Eiber et al., 2019). Knockdown of CSNK2B in mouse embryonic neural stem cells (NSC) impaired cell differentiation and reduced dendritic length and branching (Yang et al., 2018). These studies suggest a pivotal role for CSNK2B in neurodevelopmental disorders. To date, more than 40 individuals with POBINDS have been reported in the literature (Li et al., 2019; Ernst et al., 2021; Yang et al., 2021), but the genotype-phenotype correlations of POBINDS are still unclear.

In this study, we describe the clinical and genetic characteristics of eight de novo individuals with POBINDS, most of whom suffered developmental delay, generalized epilepsy, and hypotonia. Two missense, two nonsense, one frameshift, and three intron variants were detected, with only c.58G>T being reported before (Ernst et al., 2021). Minigene experiments confirmed that two intron variants (c.367+5G>A and c.367+6T>C) resulted in skipping of exon 5, leading to premature termination of mRNA transcription. Combining our data with the available literature, missense, nonsense, frameshift, and splicing site variants were found to cause POBINDS. The variant types do not reflect the severity of POBINDS. Reduced CK2 holoenzyme activity may represent a unifying pathogenesis. Missense variants in the zinc finger domain result in manageable seizures (p = 0.009) and milder intellectual disability (ID) (p = 0.003) than missense in other domains of CSNK2B. This is the first study of the genotype-phenotype correlations of CSNK2B variants and expands the knowledge of POBINDS.

**MATERIALS AND METHODS**

**Subject**

In this study, a total of eight individuals contributed clinical information and genetic data. This study was reviewed and approved by the Ethics Committee of Xiangya Hospital of Central South University following the Helsinki Declaration. The parents or legal guardian of each individual provided informed consent.

**Next-Generation Sequencing and Sanger Sequencing Verification**

Trio-whole-exome sequencing was performed on each family in this study and the methods have been described in detail in previous studies (Peng et al., 2018). All variants reported were confirmed with Sanger sequencing, and the interpretation of variants was conducted under the American College of Medical Genetics guidelines (Richards et al., 2015).

**Minigene Construction**

Minigene plasmids covering wild-type “CSNK2B_WT (exon 4–6)” and mutants “CSNK2B_Mu (exon 4–6)” (Mu1: c.367+2T>C, Mu2: c.367+5G>A, and Mu3: c.367+6T>C) were constructed using the pcDNA3.1 vector, respectively. The constructed minigene plasmids were verified by Sanger sequencing.

**Cell Culture and Transfection**

HEK293T cells and Hela cells were obtained from the Kunming Cell Bank of the Chinese Academy of Sciences (Kunming, China), and they were cultured in Dulbecco’s Modified Eagle Medium (Hyclone, United States) supplemented with 10% fetal bovine serum (Gibco, United States), 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco, United States). Cell culture was performed at 37°C in an incubator filled with 5% CO2 and 95% air. The minigene plasmids were transfected into HEK293T cells or Hela cells by LipoMax (Sudgen, China) according to the DNA transfection protocol. The cells were analyzed 48 h after transfection.

**Reverse Transcription-Polymerase Chain Reaction and Sequence Analysis**

RNA extraction methods have been described in detail in previous studies (Kong et al., 2015). Total RNA was reverse transcribed using Hifair™ 1st Strand cDNA Synthesis SuperMix for PCR (YEASEN, China). PCR was run on the T100 PCR system (Bio-Rad, United States) using PrimerStarMAX DNA Polymerase (TaKaRa Bio, Japan) according to the manufacturer’s protocol. The primers were synthesized by Tsingke Company (Target exon 4 – exon 6: 5'-CTAGAGACCCACCTGCTTAC, 3'-TAGAAGGCCACAGTCCAGG). The purified PCR products were separated and purified via 2% agarose and sequenced as described above.

**Systematic Literature Search of Reported CSNK2B Variants**

We reviewed 57 POBINDS individuals combined with our cases and reported cases (PUBMED, Human Gene Mutation Database, ClinVar, and DECIPHER) involving CSNK2B. A total of 82 POBINDS-related variants are summarized, and variants without any detailed clinical information were only aggregated in the information summary (Supplementary Table 1, Patient 58 to Patient 82). Chromosomal microdeletion/microduplications were not involved. The annotation of predicted variants effect was carried by combined annotation dependent depletion (CADD). Based on the way of affecting protein function, we classified the variants into two categories: loss-of-function (LOF, including start loss, frameshift insertion/deletion, nonsense, and splicing variant), non-LOF (including in-frame insertion/deletion and missense). In the non-LOF group, we also analyzed genotype-phenotype associations based on protein domains. MetaDome was used for bioinformatics mutation tolerance analysis (Wiel et al., 2019).

1https://cadd.gs.washington.edu/snv
2https://stuart.radboudumc.nl/metadome/dashboard
Statistical Analyses
Groups were compared using the Chi-square test, Fisher’s exact test was used where 20% or more of the grid in the Chi-square table were expected to count < 5. Significant findings (p < 0.05) were calculated as the dominance ratio with 95% confidence intervals. Statistical analysis was performed using SPSS (version 18.0, United States) software.

RESULTS
Identification of de novo CSNK2B Variants
Eight CSNK2B (NM_001320.6) variants were detected in eight individuals; all variants were de novo and absent in the gnomAD and ClinVar databases. Only one variant (c.58G>T) was reported before (Ernst et al., 2021). Variant types included nonsense (c.58G>T and c.142C>T), frameshift (c.462_465del), missense (c.325T>C and c.497T>G), and intron (c.367+5G>A, c.367+6T>C, and c.292−1G>A) variants; variant information shown in Supplementary Table 1. Sanger sequencing data of these variants in each family is shown in Supplementary Figure 1.

Clinical Features of the Eight Individuals
Phenotypes are summarized in Table 1. In the present study, three individuals were male and five were female. All individuals (8/8) had varying degrees of seizures as first signs. Five individuals (5/8) had tonic–clonic seizures, and abnormal electroencephalograms (EEGs) were reported in all individuals (8/8). One individual’s (1/8) MRI showed scattered abnormal signals in the parenchyma. Aside from individual 1, the other seven individuals (7/8) had abnormal neurodevelopmental phenotypes ranging from mild to profound ID. Three individuals (3/8) had mild dysmorphism, which manifested as partial restricted abduction and uplift of eyes, bilateral cryptorchidism, small penis, and a small jaw and prominent forehead, respectively. All individuals (8/8) had epilepsy or global developmental delay starting in the first year of life. Six individuals (6/8) had received one anti-epileptic drug (AED), and two individuals (2/8) received two AEDs. Seizures were completely controlled in seven individuals (7/8), and only one individual (1/8) had medical refraction. The AEDs most frequently reported to be helpful were levetiracetam (4/8), valproic acid (2/8), and oxcarbazepine (2/8). During the follow-up, individuals with global developmental delay (7/8) showed satisfactory improvement in motor, language, and cognitive symptoms but were still distinguishable from their healthy peers.

Minigene Splicing Assay for Intron Variants (c.367+5G>A and c.367+6T>C)
To verify that c.367+5G>A and c.367+6T>C alter the splicing of CSNK2B, we performed a minigene assay. We constructed the minigene of CSNK2B_WT and CSNK2B_Mu (Mu1: c.367+2T>C, Mu2: c.367+5G>A, and Mu3: c.367+6T>C), consisting of exons 4–6 of CSNK2B expressed in the pcDNA3.1 vector (Figure 1A). CSNK2B_Mu1 was used as a positive control for the minigene assay, which has been confirmed to skip exon 5 in primary cultured fibroblasts (Poirier et al., 2017). Next, we transfected the CSNK2B gene into HEK293T and Hela cells, respectively, and reverse transcription-polymerase chain reaction (RT-PCR) results detected a single band of predicted size (Figure 1B). After sequencing, we found that all three splicing variants resulted in skipping of exon 5 (Figures 1C,D). This skipping leads to the insertion of a premature termination codon at p.Leu98Alafs*11, confirmed by RT-PCR (Poirier et al., 2017). These data suggested that these variants resulted in the loss of function of CSNK2B.

Genotype–Phenotype Association Analysis for Reported Cases
In the combined analysis of the available literature, we summarized the details of genotypes and phenotypes from 57 cases. Among 57 cases, 48 variants were reported, including 16 missense variants (p.Asp32Asn and p.His165Arg were found in 3 patients and p.Cys137Phe and p.Arg111Pro in 2 patients), 11 splicing variants (including c.558-3T>C, c.367+5G>A, and c.367+6T>C, all confirmed after splicing), 9 frameshift variants, 8 nonsense variants (c.58G>T, c.139C>T, and c.303C>A were found in two individuals, respectively), 3 start loss variants, and 1 in-frame deletion variant. Phenotypes of CSNK2B clinical as Table 2, individuals with the same variant showed varying degrees of phenotypic heterogeneity. A total of 82 POBINDS-related variants are summarized (Figures 2A,B), 25 of them without detailed clinical information are excluded in the phenotype–genotype linkage analysis (details in Supplementary Table 1, Patients 58 to Patient 82). Based on the way they affected protein function, we classified the 57 variants with detailed phenotypes into LOF or non-LOF groups. There was no statistically significant difference in the severity of the POBINDS (epilepsy, refractory epilepsy, moderate to profound ID, dysmorphism, and hypotonia) among mutations of LOF compared to non-LOF, except dysmorphisms (p = 0.041) (Supplementary Table 2). Among 23 missense cases, the proportion of refractory epilepsy (Fisher p = 0.009) and the severity of ID (Fisher p = 0.003) were significantly lower when the mutations were located in the zinc finger region compared to other regions, respectively (Supplementary Table 3). Similar correlations were not found between other domains and phenotypes. This matched the relative tolerance calculated by the “MetaDome” algorithm (Figure 2B). These results suggest that individuals with zinc finger region variants have controllable seizures and a milder degree of ID.

DISCUSSION
CSNK2B was first reported by Poirier et al. (2017) in two individuals with early-onset epilepsy, developmental delay, hypotonia, and malformations, and was documented as the causative gene for POBINDS by OMIM in 2020.3 A total of

3https://omim.org
TABLE 1 | Genotype and phenotype details for individuals with CSNK2B variants.

| Patient | Sex/age | Variant, NM_001320.6 (variant type) | First signs/symptoms | Seizure onset/types | AEDs/efficacy | ID | Dysmorphism | Hypotonia | Behavior features | Other features |
|---------|---------|------------------------------------|----------------------|---------------------|-----------------|----|-------------|-----------|------------------|----------------|
| 1       | F/3.5 years | c.367+5G>A, (SS) | 10 months/seizure | 10 months/complex febrile seizure | VPA/seizure free | Normal | Eyes cannot move outwards and upward | – | – | Abnormal EEG |
| 2       | F/21 months | c.367+6T>C, (SS) | 3 months/seizure | 3 months/focal onset, GTC | LEV/seizure free | Mild | – | + | – | Abnormal EEG |
| 3       | M/19 months | c.58G>T p.E20* (NS) | 3 months/seizure | 3 months/GTC | LEV, OXC/seizure free | Moderate | – | + | Introverts, less interaction | Abnormal EEG |
| 4       | M/4 years | c.325T>C p.C109R (MS) | 8 months/seizure | 8 months/GTC | VPA/occasional petit mal | Mild | – | + | Autistic features | Abnormal EEG, MRI at 1 year: abnormal signals scattered in the parenchyma; speech delay; slurred speech |
| 5       | F/4 years | c.142C>T p.Q48* (NS) | 10 months/seizure | 10 months/myoclonic | LEV/seizure free | Mild | – | – | – | Abnormal EEG; motor delay, speak slowly |
| 6       | F/30 months | c.462_465del p.Asp155Alafs*70 (FS) | 4 months/seizure | Delayed neck control | 4 months/GTC | LEV, VPA/medically refractory | Profound | – | + | Poor head control, poor pursuit of light and objects, cannot sit (6 months) |
| 7       | M/4 years | c.497T>G p.M166R (MS) | 4 months/seizure | 4 months/tonic clonic | LEV/seizure free | Moderate | Bilateral cryptorchidism, small penis? | + | – | Abnormal EEG |
| 8       | F/5 years | c.292-1G>A, (SS) | 4 months/seizure | 4 months/focal seizures | OXC/seizure free | Mild | Small jaw, prominent forehead | + | – | Boundary EEG; speech delay; motor delay; motor delay |

*, *termination; AED, anti-epileptic drug; EEG, electroencephalogram; FS, frame shift; GTC, generalized tonic–clonic; ID, intellectual disability; LEV, levetiracetam; MRI, magnetic resonance imaging; MS, missense; NS, nonsense; OXC, oxcarbazepine; SS, splice site; VPA, valproic acid.
57 individuals with CSNK2B mutations have been reported to date (including eight cases in this article), and the largest sample study to date was published in *Epilepsia* by Ernst et al. (2021). The clinical phenotype of POBINDS is complex, with great inter-individual variability and uneven severity of phenotype. Although these studies have expanded the phenotype and genotype spectrum of POBINDS, the genotype-phenotype correlations in POBINDS are still unclear.

Two splicing variants (c.367+5G>A and c.367+6T>C) were located in non-canonical splicing sites. The minigene assays confirmed that these two atypical splice variants lead to skipping of exon 5, resulting in the insertion of a premature stop codon in p.Leu98Alafs*11*. A total of 11 splice variants (including three in this article) have been experimentally confirmed to lead to abnormal splicing of *CSNK2B* (Poirier et al., 2017; Yang et al., 2021). The pathogenicity of atypical splicing site variants is difficult to decipher, and our work confirmed that these variants indeed affect splicing, which is valuable for subsequent research.

Frameshift variants often bring in a premature termination codon, leading to nonsense-mediated decay (NMD) (Shoemaker and Green, 2012). However, among frameshift variants of CSNK2B, six out of nine [p.(Met132Leufs*110), p.(Asp155Alafs*71), p.(Leu167Serfs*60), p.(Pro179Tyrfs*49), p.(Asn181Thrfs*46), and p.(Lys208Glnfs*38)], induced a prolonged termination codon downstream of the wild-type termination codon, not upstream. In eukaryotes, mRNAs with these variants may not be directly identified by NMD mechanisms. NMD escape was found in other protein-coding extending like COQ8A, but enzyme activities were significantly reduced (Liu et al., 2014). The functional effects of these six frameshift variants in CSNK2B need further verification, but extensive amino acid sequence disruption cannot be ignored. Individuals with these six variants did not show any phenotypic pattern. Another 3 frameshift and 11 nonsense variants were predicted to introduce a stop codon, none of which were in the last exon or the last 50 base pairs of the penultimate exon. In this study, these variants were ranked into LOF variants. Individuals with LOF variants did not show any clear correlations in symptoms, except dysmorphisms (*p* = 0.041). There may be some objective reasons for this phenomenon, such as a small sample, varying phenotype details, and different indicators of developmental assessment in the age strata.

Interestingly, we found some duplicated mutations in the cohort, which may be hotspot mutations or regions. Ernst et al. (2021) and Yang et al. (2021) have reported three start losses with different variants (c.1A>G, c.2T>A, and c.3G>A). The effect of the start loss mutations is still unpredictable. Firstly, the phenotypes of these three individuals are polytropic, c.1A>G showed only mild speech and motor developmental

---

**FIGURE 1** | Minigene splicing assay for intron variants. (A) Schematic diagram of minigene plasmid construction. Red bases are targeted sites. (B) Minigene was transfected into HEK293 cells and Hela cells, respectively. A single band was detected by RT-PCR with a lower molecular weight than wild-type CSNK2B. (C,D) Sequencing of the above bands revealed that three splicing variants (c.367+2T>C, c.367+5G>A, and c.367+6T>C) all resulted in exon 5 skipping and early termination of the amino acids.
The untranslated region (UTR) of exon 5 (c.292-367) may be a process, such as organogenesis (Bandyopadhyay et al., 2016). Refractory. These phenotype profiles suggest that mutations at the epilepsy, both of which manifested as absence epilepsy and drug-refractory. Three individuals had seizures and two were diagnosed with ID, and malformations. In these four individuals, some mutual characteristics were found, such as moderate to severe ID, and malformations. Three individuals had seizures and two were diagnosed with epilepsy, both of which manifested as absence epilepsy and drug-refractory. These phenotype profiles suggest that mutations at the c.G94 mutation may be involved in signaling a variety of developmental processes, such as organogenesis (Bandyopadhyay et al., 2016). The untranslated region (UTR) of exon 5 (c.292-367) may be a hotspot region for CSNK2B mutations. A total of 11 individuals were reported in this region, 5 individuals with detailed phenotypes available. Four individuals were diagnosed with epilepsy, all with effective antiepileptic treatment. Three with seizures before 6 months of age. The degree of ID varied from mild to severe, except one individual, had normal development (c.367+5G>A), and three cases had malformations (c.292-1G>A, c.367+2T>C, and c.367+5G>A). Although all five splice site mutations have been experimentally confirmed to cause skipping of exon 5 (except for c.292-1G>A), the varied clinical phenotypes suggest that CSNK2B may influence POBINDS onset and progression through some unknown pathways.

Regarding the location of the mutation, the individuals with variants in the zinc finger domain (residues 105–140) had manageable seizures and milder ID, which was inextricably linked to the structure and function of CK2β.

Zinc finger structures play a crucial role in the regulation of transcription, adaptation of protein interactions, and post-transcriptional regulation in eukaryotes (Laity et al., 2001; Ecco et al., 2017). Zinc finger mutations (cys109, 114) result in the inability of CK2β to form dimers and loss of the interaction with the catalytic subunit CK2α, which is accompanied by increased degradation of the mutant protein (Canton et al., 2001). The individual in our cohort (c.325T>C) was mildly affected and had manageable epilepsy, mild ID, and mainly language delay. This does not appear to be parallel to the severity of the mutation. However, the situation in vivo is complex, and developmental delay may be a direct cause of seizures or due to genetic pleiotropy. Increased degradation of CK2β degradation may trigger a compensatory mechanism that regulates CK2β protein levels. Our data reveal corresponding associations from both clinical and bioinformatics analysis, suggesting that the mutation in this region may be less harmful, and also worth further functional study.

In addition to the zinc finger region, CK2β includes the N-terminal (residues 1–54) containing the autophosphorylation site, an acidic groove region (residues 55–77), and a C-terminal (residues 171–215) that stabilizes the CK2β-CK2α interaction (Reed et al., 1994; Bidwai et al., 1995). We compared missense variants across domains, and the results were not convincing due to the small number of variants. The C-terminal-truncated CK2β loses its ability to bind stably to the catalytic subunit (Sarno et al., 2000). p.(Pro179Tyrfs*49)-mutated CK2β is unable to bind to the CK2α, although it is still expressed (Nakashima et al., 2019). The frameshift of CSNK2B (c.499del) resulted in decreased protein expression (Yang et al., 2021). These studies suggest that the CSNK2B mutation is likely to affect the function of CK2 in a haploinsufficient manner. However, we cannot exclude a dominant-negative effect of CK2β. It was previously shown that although CSNK2B heterozygous mice did not differ significantly from wild-type mice in CK2β expression levels, some of the heterozygous mice failed to survive (Blond et al., 2005). This may have been due to the mutated CK2β forming non-functional tetramers that inhibited the normal catalytic activity of the wild-type CK2α. Such phenomena are not uncommon in proteins that perform functions in multimeric forms (Ahn et al., 2003). The reduced CK2 holoenzyme activity may represent a uniform pathogenesis.

---

TABLE 2 | Phenotypes of CSNK2B clinical and epilepsy characteristics (n = 57).

| Phenotype                        | All (n = 57) | LOF (n = 34) | Non-LOF (n = 23) |
|---------------------------------|-------------|-------------|-----------------|
| Seizures                        | 51          | 31          | 19              |
| Epilepsy                        | 48          | 31          | 17              |
| Onset of epilepsy               |             |             |                 |
| 0–6 months                      | 30          | 18          | 12              |
| 7–12 months                     | 8           | 6           | 2               |
| 13–24 months                    | 4           | 3           | 1               |
| 25–36 months                    | 3           | 2           | 1               |
| >36 months                      | 3           | 2           | 1               |
| Epilepsy types                  |             |             |                 |
| Generalized tonic or            |             |             |                 |
| tonic-clonic seizures           | 27          | 17          | 10              |
| Absence seizures                | 6           | 2           | 4               |
| Myoclonic seizures              | 14          | 10          | 4               |
| Focal onset seizures            | 9           | 5           | 4               |
| Multiple seizure types          | 18          | 11          | 7               |
| Antiepileptic drugs used        | 38          | 25          | 13              |
| Effective epilepsy control      | 28          | 18          | 11              |
| GDD/ID                          | 43          | 29          | 20              |
| Motor delay                     | 37          | 26          | 16              |
| Speech delay                    | 37          | 25          | 17              |
| Moderate to profound            | 21          | 14          | 10              |
| Hypotonia                       | 17          | 13          | 8               |
| Dysmorphisms                    | 17          | 10          | 13              |
| Problematic behavior            | 10          | 8           | 3               |

GDD, global developmental delay; ID, intellectual disability; LOF, loss of function, including start loss, frameshift insertion/deletion, nonsense, and splicing variants; non-LOF, including in-frame insertion/deletion.

There was no statistically significant difference in the characteristics of the POBINDS among mutations of LOF compared to non-LOF, except dysmorphisms (details in Supplementary Table 2). References and databases for all mutation information are detailed in Supplementary Table 1.
The severity of the neurological phenotype ultimately depends on the spatiotemporal distribution and catalytic activity of CK2. The CK2 holoenzyme is a heterotetramer composed of two catalytic subunits (α/α') and two regulatory subunits (β), which can bind as αβ2, αα'β2, or α'2β2 forms. During early development (embryonic and fetal stages), the mRNA levels of CK2β were significantly higher than those in childhood and adulthood (Yang et al., 2018). CK2 activity was higher in cortical pyramidal neurons and large striatal neurons than in other neuronal populations (Castello et al., 2017). Interestingly, in different brain regions of adult rats, the expression of each subunit of CK2 is different at the transcriptional level and the protein level (Castello et al., 2017). This may form distinguishing CK2 heterotetramers in different brain regions, resulting in different enzymatic activity of CK2.

In addition, CK2 is involved in protein phosphorylation, and these affected proteins/signaling pathways may be the main cause of the progression of neurodevelopmental disorders. CK2 catalyzes the phosphorylation of Kv3.1 and calmodulin (Miller, 2000; Macica and Kaczmarek, 2001), the latter of which directly affects the stability of KCNQ2 channels (Renain and Villalobo, 2002). CK2 is abundantly expressed in the postsynaptic density (Soto et al., 2004), and inhibition of CK2 blocks N-methyl-D-aspartate receptor-dependent synaptic transmission and long-term potentiation (Kimura and Matsuki, 2008). Meanwhile, knockdown of CSNK2B not only impaired cell differentiation of mouse embryonic NSC (Yang et al., 2018) but also disrupted the migration of mouse immortalized neuronal GN11 cells (Lettieri et al., 2019). The deletion of CSNK2B in embryonic NSC impaired the proliferation of forebrain NSCs and inhibited the differentiation of NSCs into oligodendrocyte precursor cells, resulting in defects in brain development (Huillard et al., 2010). Conditional knockout CSNK2B mice showed an age-dependent reduction in grip strength, impaired neuromuscular transmission, and inordinate synaptic gene expression (Eiber et al., 2019). Abnormal emotional behavior, including autistic behavior, irritability, depression, and hyperactivity, may be associated with abnormalities in the CK2-mediated dopamine signaling pathway (Rebholz et al., 2009; DiCarlo and Wallace, 2022). The above CK2 signal involvements underlie the phenotypes of neurodevelopmental disorders such as epilepsy, developmental delay, hypotonia, and dysmorphic disorders.

Limitations of this study include the heterogeneity of the clinical data. When analyzing the reported cases, we relied heavily on the authors' descriptions of the individuals, and the data lacked a standardized assessment. Especially concerning the judgment of developmental delay, age stratification needs to
be introduced to standardize the determination of the degree of developmental delay. The reported age of some patients is too young, and some late-onset neurodevelopmental symptoms need to be determined by long-term follow-up. Additionally, the statistical power of our Chi-square and Fisher's exact test was generally below 0.8, which may omit some true positive results. This question requires more samples to solve. Moreover, the mechanism by which CSNK2B variants cause CK2 dysfunction remains unclear, especially the effect of missense variants on CK2, which requires more experimental models. With the increase of the functional study and refinement of phenotypic profiles, the clarity of genotype-phenotype correlations is expected to be further improved.

In conclusion, this study further enriched the phenotype-genotype profile of POBINDS. Minigene experiments confirmed that two intron variants resulted in skipping exon 5, leading to a premature termination of mRNA transcription. The pathogenicity of intronic variants requires more experiments to decipher. Taken together, our analysis results showed that missense, nonsense, frameshift, and splicing variants were common forms of CSNK2B variants, and individuals with variants in the zinc finger domain had manageable seizures and milder ID. The variant types do not reflect the severity of the POBINDS. Determining further genotype-phenotype correlations in POBINDS requires more functional research and refinement of phenotypic profiles.

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

This study was reviewed and approved by the Ethics Committee of Xiangya Hospital of Central South University. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

REFERENCES

Ahn, W., Lee, M. G., Kim, K. H., and Mualem, S. (2003). Multiple effects of Xiangya Hospital of Central South University. Written

AUTHOR CONTRIBUTIONS

FY, WZ, and NP designed the research. WZ, FHY, JP, and NP performed the research. WZ, NP, and FY performed the data analysis. WZ, FHY, NP, and FY wrote the manuscript. All authors read, edited, and approved the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (81701541 and 81771408), the Hunan Key Research and Development Program (No. 2019SK2081), and the Fundamental Research Funds for the Central Universities of Central South University (2019zzts347).

ACKNOWLEDGMENTS

We thank the Clinical Research Center for Children Neurodevelopmental Disabilities of Hunan Province for providing the platform and the personnel who work there for giving support and guidance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins.2022.892768/full#supplementary-material

AUTHOR CONTRIBUTIONS

FY, WZ, and NP designed the research. WZ, FHY, JP, and NP performed the research. WZ, NP, and FY performed the data analysis. WZ, FHY, NP, and FY wrote the manuscript. All authors read, edited, and approved the manuscript.

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

REFERENCES

Ahn, W., Lee, M. G., Kim, K. H., and Mualem, S. (2003). Multiple effects of SERCA2b mutations associated with darier's disease. J. Biol. Chem. 278, 20795–20801. doi: 10.1074/jbc.M301638200

Bandyopadhyay, M., Arbet, S., Bishop, C. P., and Bidwai, A. P. (2016). Drosophila protein kinase CK2: genetics, regulatory complexity and emerging roles during development. Pharmaceuticals 10:4. doi: 10.3390/ph10010004

Benaim, G., and Villalobo, A. (2002). Phosphorylation of calmodulin. Functional implications. Eur. J. Biochem. 269, 3619–3631. doi: 10.1046/j.1432-1033.2002.03038.x

Benkiranke, M., Marelli, C., Guissart, C., Roubertie, A., Ollagnon, E., Choumert, A., et al. (2021). High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families. Genet. Med. 23, 2160–2170. doi: 10.1038/s41436-021-01250-6

Bidwai, A. P., Reed, J. C., and Glover, C. V. (1995). Cloning and disruption of CKB1, the gene encoding the 38-kDa beta subunit of Saccharomyces cerevisiae casein kinase II (CKII). Deletion of CKII regulatory subunits elicits a salt-sensitive phenotype. J. Biol. Chem. 270, 10395–10404. doi: 10.1074/jbc.270.18.10395

Brendan, O., Jensen, H. H., Buchou, T., Cochet, C., Issinger, O., and Boldyreff, B. (2005). Knocking out the regulatory beta subunit of protein kinase CK2 in mice: gene dosage effects in ES cells and embryos. Mol. Cell. Biochem. 274, 31–37. doi: 10.1016/j.molbiorev.2021.12.017

Canton, D. A., Zhang, C., and Litchfield, D. W. (2001). Assembly of protein kinase CK2: investigation of complex formation between catalytic and regulatory subunits using a zinc-finger-deficient mutant of CK2beta. Biochem. J. 358(Pt 1), 87–94. doi: 10.1042/0264-6021:3580087

Castello, J., Ragnauth, A., Friedman, E., and Rebolz, H. (2017). CK2-A: an emerging target for neurological and psychiatric disorders. Pharmaceuticals 10:7. doi: 10.3390/ph10010007

Chen, S., Xie, W., Liu, Z., Shan, H., Chen, M., Song, Y., et al. (2020). CRISPR start-loss: a novel and practical alternative for gene silencing through base-editing-induced start codon mutations. Mol. Ther. Nucleic Acids 21, 1062–1073. doi: 10.1016/j.omtn.2020.07.037

DiCarlo, G. E., and Wallace, M. T. (2022). Modeling dopamine dysfunction in autism spectrum disorder: from invertebrates to vertebrates. Neurosci. Biobehav. Rev. 133:104494. doi: 10.1016/j.neubiorev.2021.12.017

Ecco, G., Imbeault, M., and Trono, D. (2017). KRAB zinc finger proteins. Development 144, 2719–2729. doi: 10.1242/dev.132605
Eiber, N., Rehman, M., Kravic, B., Rudolf, R., Sandri, M., and Hashemolhosseini, S. (2019). Loss of protein kinase Csnk2b/Ck2β at neuromuscular junctions affects morphology and dynamics of aggregated nicotinic acetylcholine receptors, neuromuscular transmission, and synaptic gene expression. Cells 8:940. doi: 10.3390/cells8090940

Ernst, M. E., Baugh, E. H., Thomas, A., Bier, L., Lippa, N., Stong, N., et al. (2021). Csnk2b: a broad spectrum of neurodevelopmental disability and epilepsy severity. Epilepsia 62, e103–e109. doi: 10.1111/epi.16931

Graham, K. C., and Litchfield, D. W. (2000). The regulatory beta subunit of protein kinase CK2 modulates formation of tetrameric CK2 complexes. J. Biol. Chem. 275, 5003–5010. doi: 10.1074/jbc.275.7.5003

Guerra, B., Siemer, S., Boldyreff, B., and Issinger, O. G. (1999). Protein kinase CK2: evidence for a protein kinase CK2beta subunit fraction, devoid of the catalytic CK2alpha subunit, in mouse brain and testicles. FEBS Lett. 462, 353–357. doi: 10.1016/s0014-5793(99)01553-7

Huillard, E., Ziercher, L., Blond, O., Wong, M., Deloulme, J., Souchelnytskyi, S., et al. (2010). Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Mol. Cell. Biol. 30, 2737–2749. doi: 10.1128/MCB.01566-09

Kimura, R., and Matsuki, N. (2008). Protein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampus. J. Physiol. 586, 3195–3206. doi: 10.1111/jphysiol.2008.151894

Kong, H., Yin, F., He, F., Omran, A., Li, L., Wu, T., et al. (2015). The effect of miR-132, miR-146a, and miR-155 on MRP8/TLR4-Induced Astrocyte-Related inflammation. J. Mol. Neurosci. 57, 28–37. doi: 10.1007/s12031-015-0574-x

Latty, J. H., Lee, B. M., and Wright, P. E. (2001). Zinc finger proteins: new insights into structural and functional diversity. Curr. Opin. Struc. Biol. 11, 39–46. doi: 10.1016/s0959-440x(00)00167-6

Lettieri, A., Borgo, C., Zanieri, L., D’Amore, C., Oleari, R., Paganoni, A., et al. (2019). Protein kinase CK2 subunits differentially perturb the adhesion and migration of GN11 cells: a model of immature migrating neurons. Int. J. Mol. Sci. 20:5951. doi: 10.3390/ijms20235951

Li, J., Gao, K., Cai, S., Liu, Y., Wang, Y., Huang, S., et al. (2019). Germine de novo variants in Csnk2b in Chinese patients with epilepsy. Sci. Rep. 9:17909. doi: 10.1038/s41598-019-53484-9

Liu, Y. T., Hershenson, J., Plagnol, V., Fawcett, K., Duberley, K. E. C., Preza, E., et al. (2014). Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation. J. Neurol. Neurosurg. Psychiatry 85, 493–498. doi: 10.1136/jnnp-2013-306483

Macia, C. M., and Kaczmarek, L. K. (2001). Casein kinase 2 determines the voltage dependence of the Kv3.1 channel in auditory neurons and transfected cells. J. Neurosci. 21, 1160–1168. doi: 10.1523/JNEUROSCI.21-04-01160.2001

Miller, C. (2000). An overview of the potassium channel family. Genome Biol. 1:S4. doi: 10.1186/GB-2000-1-4-reviews0004

Nakashima, M., Tohyama, I., Nakagawa, E., Watanabe, Y., Siew, C. N. G., Kwong, C. S., et al. (2019). Identification of de novo Csnk2a1 and Csnk2b variants in cases of global developmental delay with seizures. J. Hum. Genet. 64, 313–322. doi: 10.1038/s10048-018-0559-z

Niefind, K., Guerra, B., Ermakowa, L., and Issinger, O. G. (2001). Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 20, 5320–5331. doi: 10.1093/emboj/20.19.5320

Peng, J., Wang, Y., He, F., Chen, C., Wu, L. W., Yang, L. F., et al. (2018). Novel West syndrome candidate genes in a Chinese cohort. CNS Neurosci. Ther. 24, 1196–1206. doi: 10.1111/cns.12860

Poirier, K., Hubert, L., Viot, G., Rio, M., Billuart, P., Besmond, C., et al. (2017). Csnk2b splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy. Hum. Mutat. 38, 932–941. doi: 10.1002/humu.23270

Rehholz, H., Nishi, A., Liebscher, S., Nairn, A. C., Flajolet, M., and Greengard, P. (2009). CK2 negatively regulates Galphas signaling. Proc. Natl. Acad. Sci. U.S.A. 106, 14096–14101. doi: 10.1073/pnas.0906857106

Reed, J. C., Bidwai, A. P., and Glover, C. V. (1994). Cloning and disruption of CK2β, the gene encoding the 32-kDa regulatory beta’-subunit of Saccharomyces cerevisiae casein kinase II. J. Biol. Chem. 269, 18192–18200.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424. doi: 10.1038/gim.2015.30

Sarno, S., Marin, O., Boschetti, M., Pagano, M. A., Meggio, F., and Pinna, L. A. (2000). Cooperative modulation of protein kinase CK2 by separate domains of its regulatory beta-subunit. Biochemistry 39, 12324–12329. doi: 10.1021/bi001143I

Shoemaker, C. J., and Green, R. (2012). Translation drives mRNA quality control. Nat. Struct. Mol. Biol. 19, 594–601. doi: 10.1038/nsmb.2301

Soto, D., Pancetti, F., Marengo, J. J., Sandoval, M., Sandoval, R., Orrego, F., et al. (2004). Protein kinase CK2 in postsynaptic densities: phosphorylation of PSD-95/SAP90 and NMDA receptor regulation. Biochem. Biophys. Res. Commun. 322, 542–550. doi: 10.1016/j.bbrc.2004.07.158

Wiel, L., Baekman, C., Gilissen, D., Veltman, J. A., Vriend, G., and Gilissen, C. (2019). MetaDome: pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. Hum. Mutat. 40, 1030–1038. doi: 10.1002/humu.23798

Yang, C., Li, X., Wu, Y., Shen, Z., Zeng, Y., Xiong, Q., et al. (2018). Comprehensive integrative analyses identify GLT8D1 and Csnk2b2 as schizophrenia risk genes. Nat. Commun. 9:17388. doi: 10.1038/s41467-018-03247-3

Yang, S., Wu, L., Liao, H., Lu, X., Zhang, X., Kuang, X., et al. (2021). Clinical and genetic analysis of six Chinese children with Poirier-Bienvenu neurodevelopmental syndrome caused by Csnk2b mutation. Neurogenetics 22, 323–332. doi: 10.1007/s10048-021-00649

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Ye, Chen, Peng, Pang and Yin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.